Eighty-three percent is the number that defines Cabaletta Bio’s regulatory calculus right now: that share of dermatomyositis patients in RESET-Myositis who hit a moderate-to-major Total Improvement Score response at 16 weeks, off all immunomodulators — and every single one of those patients has maintained that response through follow-up as long as 1.5 years. The registrational cohort is designed to require no more than 50% of patients to hit that same endpoint for a positive study. That gap between observed performance and the success threshold is unusually wide, and it sets a meaningful clinical foundation for the planned 2027 BLA submission for rese-cel (resecabtagene autoleucel).
Systemic sclerosis with ILD is emerging as the second pivotal indication, and the Phase 1/2 data justify that ambition. At 36 weeks off immunomodulators, 83% of SSc patients hit rCRISS-25 and 67% hit rCRISS-50, with a median 7.5% improvement in percent predicted FVC in the ILD subgroup — a population where approved agents like nintedanib slow decline rather than reverse it. Responses in SSc appear to deepen with longer follow-up, which is the opposite of what typically occurs with conventional immunosuppression. A single-arm registrational study in roughly 25 SSc-ILD patients is set to begin in Q4 2026. The safety profile holds: 87% of SSc patients experienced no CRS beyond a transient Grade 1 fever, with one previously reported Grade 3 ICANS the only notable neurological event across 15 patients.
The genuinely unsettled question — and the one with the largest commercial implication — is whether preconditioning chemotherapy can be eliminated entirely. The first PC-free lupus data are early and ambiguous by design: two patients at the lowest dose, one of whom achieved deep B cell depletion comparable to what preconditioning-treated patients have shown before achieving immune reset. That pharmacodynamic signal, however tentative, suggests the lowest dose may be a threshold rather than a ceiling. Higher-dose PC-free cohorts are now enrolling in both lupus and pemphigus vulgaris. Rese-cel already carries RMAT designation for myositis and lupus, which confers rolling review eligibility — but the preconditioning question will determine whether the therapy can scale beyond tertiary centers and into outpatient rheumatology practices.
The single most consequential data readout to track is the PC-free lupus dose escalation: if the second or third cohort replicates the deep B cell depletion seen in one of the first two patients — without chemotherapy — the addressable population expands dramatically and the competitive positioning of rese-cel changes in kind.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
